Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $73 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a $73 price target.
July 20, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PTC Therapeutics has received an Overweight rating from Cantor Fitzgerald, with a maintained price target of $73.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for PTC Therapeutics. The maintained price target of $73 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100